U.S. markets close in 1 hour 45 minutes

  • S&P 500

    4,011.70
    +38.81 (+0.98%)
     

  • Dow 30

    33,141.56
    +160.01 (+0.49%)
     

  • Nasdaq

    13,456.83
    +209.96 (+1.58%)
     

  • Russell 2000

    2,248.18
    +27.66 (+1.25%)
     

  • Crude Oil

    61.56
    +2.40 (+4.06%)
     

  • Gold

    1,728.50
    +12.90 (+0.75%)
     

  • Silver

    24.93
    +0.40 (+1.62%)
     

  • EUR/USD

    1.1777
    +0.0046 (+0.39%)
     

  • 10-Yr Bond

    1.6840
    -0.0620 (-3.55%)
     

  • GBP/USD

    1.3825
    +0.0043 (+0.31%)
     

  • USD/JPY

    110.6300
    -0.0650 (-0.06%)
     

  • BTC-USD

    58,808.76
    -503.96 (-0.85%)
     

  • CMC Crypto 200

    1,198.14
    -5.03 (-0.42%)
     

  • FTSE 100

    6,737.30
    +23.67 (+0.35%)
     

  • Nikkei 225

    29,388.87
    +210.07 (+0.72%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Is Amazon stock silly cheap?

Brian Sozzi
·Editor-at-Large
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The time is ripe to pounce on Amazon's stock, argues Guggenheim analyst Robert Drbul. 

"Over the past six months, Amazon shares have declined ~2% vs. a 19% increase for the S&P 500. While the company will be up against difficult top-line comparisons in coming quarters, we see a favorable backdrop for shares through the balance of 2021 as 1) top-line growth rates are likely to remain robust (in the 20% range, by our estimates), 2) AWS and cloud computing trends remain strong, and 3) profitability gains materialize as high-margin business segments scale further and as Amazon laps heavy investment made in 2020 (including COVID-related spend and fulfillment center expansion)," Drbul writes in a new research note. 

Drbul sees fair value on Amazon (AMZN) to $4,000 a share, up about 30% from current levels. 

To be sure, Amazon's usually hot stock has been stuck in the mud of late. Year-to-date, Amazon shares are down 4% versus a 7% gain on the S&P 500 and 4.4% pop on the Nasdaq Composite. It's the second worst-performing component of the closely watched FAANG index (Facebook, Amazon, Apple, Netflix and Google) of tech giants — Apple shares have shed 7% this year. 

NORTH LAS VEGAS, NEVADA - MARCH 31: An exterior view shows an Amazon fulfillment center on March 31, 2021 in North Las Vegas, Nevada. The company is offering employees COVID-19 vaccinations at the facility for eight days. (Photo by Ethan Miller/Getty Images)
NORTH LAS VEGAS, NEVADA - MARCH 31: An exterior view shows an Amazon fulfillment center on March 31, 2021 in North Las Vegas, Nevada. The company is offering employees COVID-19 vaccinations at the facility for eight days. (Photo by Ethan Miller/Getty Images)

Most Wall Street analysts point to the potential for slowing sales and earnings growth this year as Amazon cycles a major pickup in business at the start of the pandemic in 2020 for the stock's weakness. Others have voiced some concern about Amazon founder and CEO Jeff Bezos preparing to step aside as CEO in the third quarter. 

Drbul thinks the concerns on the fundamentals of Amazon's business are overblown, however. 

"In our view, Amazon's retail business appears as strong as it ever has. Our 2021E full year growth forecast incorporates a return to the pre-COVID trajectory in the low-20% range, which we believe is achievable despite the challenging year-over-year compare given our expectation for continued elevated rates of growth in 1H21, particularly 1Q (+42%). Our model incorporates a more normalized level of growth in 2Q-4Q (+high-teens growth), which could prove conservative (2Q in particular) given ongoing COVID-related restrictive measures. In addition, we would highlight the expansion and rollout of free one-day delivery with Prime and robust rates of membership growth as additional supportive factors that should help Amazon "comp the COVID comp," contends Drbul. 

Adds Drbul, "We believe AWS remains in the early innings of its growth potential and should benefit in coming quarters/years as companies accelerate their shift to the cloud, in part driven by COVID."

Brian Sozzi is an editor-at-large and anchor at Yahoo Finance. Follow Sozzi on Twitter @BrianSozzi and on LinkedIn.

What’s hot from Sozzi:

Watch Yahoo Finance’s live programming on Verizon FIOS channel 604, Apple TV, Amazon Fire TV, Roku, Samsung TV, Pluto TV, and YouTube. Online catch Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, SmartNews, and LinkedIn.

Recommended Stories

  • Fed officials on the fence about adopting digital US dollar

    The Federal Reserve is continuing its research on the use of a central bank-issued digital currency (CBDC), but key officials are saying not to expect any Fed-issued digital dollars any time soon.

  • Compass IPO debut: Here's how the stock is doing

    Compass (COMP), the real estate tech company, backed by Softbank, went public on the New York Stock Exchange on Thursday. Shares opened at $21.25 popping as much as 22% in the first few minutes of trading.

  • Cramer Says Forget Tech And Look To These Sectors In Q2

    As the second quarter kicks off, CNBC host Jim Cramer has cautioned against investing in tech and healthcare stocks. What Happened: Cramer said he is bullish on industrial and bank stocks and advised investors to focus on the boom-and-bust cyclical stocks amid a booming economy. “As the second quarter gets rolling, I think this market will become even kinder to the industrials and ... the banks and even less hospitable to tech and health care,” Cramer said on CNBC’s "Mad Money" show. Cramer touted steel products supplier Cleveland-Cliffs Inc. (NYSE: CLF) as a likely winner in the second quarter. See also: Best Growth Stocks Right Now According to Cramer, the company is putting up numbers that are attracting money from big fund investors who are shifting away from tech stocks such as Amazon.com Inc. (NASDAQ: AMZN), Apple Inc. (NASDAQ: AAPL), Zscaler Inc. (NASDAQ: ZS) and ServiceNow Inc. (NYSE: NOW). The shares of all the four tech companies are down in a range of 5% to 14% for the year-to-date period. Cleveland-Cliffs’ stock jumped almost 17% in Wednesday’s trading session after the company provided updated financial guidance for the first and second quarters as well as for fiscal 2021. The company will announce its first-quarter earnings results on April 22. Money managers are interested in companies that can deliver the biggest upside surprises and are not bothered about the most exciting long-term growth stories, according to Cramer. He also noted that higher inflation as the economy gains momentum could be devastating for stocks of companies that may represent future growth. See Also: Return On Capital Employed Overview: Cleveland-Cliffs Why It Matters: U.S. stocks closed mostly higher on Wednesday, the last day of the first quarter. The S&P 500 added 0.4% and the tech-heavy Nasdaq Composite rose 1.5%, while the Dow Jones Industrial Average declined 0.3%. However, Cramer called the Nasdaq Composite’s advance a “countertrend rally.” While tech stocks gained strongly last year amid the pandemic, investors are now shifting focus to recovery and cyclical stocks amid increased optimism about government spending and Covid vaccinations. See more from BenzingaClick here for options trades from BenzingaElon Musk Nominated To The Board Of Miss Universe Parent EndeavorTesla To Miss Street Estimate On Q1 Deliveries But Don't Be Alarmed, Says Munster© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Kansas City Chiefs QB Patrick Mahomes: 'I am trying to build a business empire'

    Yahoo Finance talks with star Kansas City Chiefs QB Patrick Mahomes about his budding business empire.

  • Palantir CEO Karp Discloses $10.3 Million Stock Sale. That’s the Tip of the Iceberg.

    Palantir co-founder Stephen Cohen made a similar filing, disclosing the sale of 173,595 shares for total proceeds of about $3.9 million shares.

  • Stock market news live updates: S&P 500 tops 4,000 for the first time, Nasdaq gains more than 1%

    The S&P 500 logged a record high on Wednesday, closing out its best month since November

  • Cathie Wood’s Ark Innovation ‘ill-prepared to grapple with a major plot twist’ in stock market, warns Morningstar analyst

    Cathie Wood's flagship Ark Innovation fund has had a rough March after a scintillating stretch for the once-highflying exchange-traded fund, but there may be more gut-wrenching volatility in store for ETF, according to at least one analyst, who cautions investors to be wary.

  • 2 “Strong Buy” Stocks Insiders Are Snapping Up

    One strategy for selecting top stocks is to track insider transactions. After all, if insiders are dipping into their own pockets you can imagine it’s because they believe the stock looks compelling. A Harvard study revealed that insider purchases earn “abnormal” returns of more than 6% per year. The authors of the study conclude that insider buyers “have a good feel for near-term developments within their firm.” The advantage of following these insiders isn’t just that they are privy to data which the rest of us don’t necessarily know – it’s also that they are held responsible for their decisions. Company officers can’t just make trading choices based on personal preference or profit. They must account for their choices to board members and shareholders – and that audience wants to make money, too. So, when corporate insiders start buying up stock in their own company, it’s a strong signal for investors. Bearing this in mind, we used the Insiders’ Hot Stocks tool from TipRanks to point us in the direction of “Strong Buy” stocks the insiders are snapping up. We found two names flashing signs of strong insider buying that warrant a closer look. Epizyme (EPZM) We’ll start with Epizyme, a clinical stage biotechnology company focused on the development of novel epigenetic medicines designed to specifically target the genetic causes of various cancers, including non-Hodgkin lymphoma (NHL) and certain genetically defined solid tumors. The company’s flagship product, tazemetostat, was approved last year for use as a monotherapy in two indications: epithelioid sarcoma, and non-Hodgkin lymphoma. The company is also planning several clinical trials to measure tazemetostat’s efficacy as a combination drug against NHL and several solid tumor cancers, including some types of prostate cancer. Having a marketable drug approved and available for prescription is the goal of every biotech pharma company – so Epizyme has achieved a major milestone with tazemetostat. The drug, marketed as Tazverik, brought in net revenues of $4.5 million in 4Q20, slightly more than half of the company’s quarterly revenue total of $8.4 million. For the full year 2020, the company’s top line came in at $15.8 million; Tazverik’s share was $11.5 million. Looking at the pipeline, Epizyme has upcoming Phase 1b studies of Tazverik in the treatment of castration-resistant prostate cancer. This study is already fully enrolled, and the initial safety and activity data is expected to come in 2H21. Additional studies of Tazverik in the treatment of heme and solid tumors are slated to begin later this year. Turning to the inside trades, we note that David Mott, of Epizyme’s Board of Directors, made a purchase of $500,099 in EPZM shares. He made the purchase, totaling 62,717 shares, in three tranches on March 25 and 26. His display of confidence gets the backing of Wedbush's David Nierengarten. The 5-star analyst rates EPZM an Outperform (i.e. Buy), and his $27 price target implies a robust upside of 212% in the coming year. (To watch Niergarten’s track record, click here) “[We] are encouraged by the progress EPZM made with marketing Tazverik for the first year. After the challenges of the pandemic environment recede, we expect more rapid adoption in the clinic. EPZM is also looking to partner the marketing of Tazverik abroad. EPZM has a strong cash position with runway into 2023," Nierengarten commented. Overall, it’s clear that Wall Street generally agrees with Nierengarten on this one. There are 8 recent reviews of this stock, and they break down strongly – by 6 to 2 – in favor of Buy versus Hold, giving EPZM its Strong Buy analyst consensus rating. The share are trading for $8.66, and their $18.67 average price target suggests a one-year upside of ~116%. (See EPZM stock analysis on TipRanks) Verrica Pharmaceuticals (VRCA) Next up is Verrica, a dermatology-focused therapeutics company working on new treatments and medical interventions for a wide range of skin conditions. The company has three drug candidates in the pipeline – V-102, V-103, and LTX-315. Of these, the latter two are in the pre-IND process with the FDA, while the first, V-102, is waiting for an FDA approval as a treatment for molluscum contagiosum. V-102’s NDA is actually a resubmission; the process was started last year, and the FDA send a CRL in July. Verrica resubmitted the NDA in December, and expects acceptance later this year, and the PDUFA date for this application is June 23. Molluscum contagiosum affects some 6 million people in the US, so the patient base for an effective treatment is there. In the meantime, the company is pursuing two additional studies of V-102, as a treatment for common warts and external genital warts. Verrica priced a public offering of stock on March 25, offering over 2 million shares at $14.75 each. And that brings us to the insider purchase. Board member Paul Manning, who is also a 10% owner of the company, picked up over 739,000 shares, paying more than $10.91 million. Turning to the analyst community, H.C. Wainwright, Oren Livnat believes the company has a lot going for it and a bright future. “We see high probability of final approval and believe Verrica more than likely has satisfactorily addressed the items in the prior Complete Response Letter, which necessitated a minor device design update, and additional Human Factors and stability work. We believe FDA should be keen to approve a properly regulated cantharidin product, given all that is available now is poorly regulated, compounded volatile product, and there is nothing approved to treat MC," Livnat wrote. The analyst added, "Assuming approval, Verrica hopes to launch by end-August. We continue to project a modest ramp through 2022 as Verrica implements an innovative forward-deployed inventory model… [we] continue to project peak sales of about $375M.” In line with these comments, Livnat rates VRCA shares as a Buy, with a $24 price target to indicates a 58% upside on the one-year horizon. (To watch Livnat’s track record, click here) There are only two recent reviews on record for Verrica – but both of them are to Buy the stock, making the Moderate Buy rating unanimous. VRCA is priced at $15.04, with an average price target of $23.33 suggesting a 55% one-year upside potential. (See VRCA stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • 4 Dow Jones Stocks To Buy And Watch In April 2021: Apple, Microsoft Jump

    The Dow Jones Industrial Average remain near record highs at the end of March, as the current stock market rally continues. The best Dow Jones stocks to buy and watch in April 2021 are Apple, Boeing, Disney and Microsoft.

  • Here’s one big clue Americans are bracing for higher taxes under Joe Biden

    Now, data suggests more people don’t want to take the chance they’ll have to pay higher taxes on that money in the future. With President Joe Biden unveiling details Wednesday on a $2.3 trillion infrastructure spending plan powered by corporate tax hikes, information from Fidelity Investments could be an indication of what some individual taxpayers think the president has in store for them. “Income tax rates have no place to go but up,” said Michelle Gessner of Gessner Wealth Strategies in Houston, Texas.

  • Our tax system fails to account for race: Expert

    Dorothy Brown, Asa Griggs Candler Professor at Emory University School of Law and author of “The Whiteness of Wealth”, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss how tax policies impact the racial wealth gap.

  • Crypto Exchange Luno Hires CFO of Digital Banking Giant Monzo

    Alwyn Jones is the latest in a group of digital banking executives to join crypto firms.

  • Canada's cash-rich oil sands firms face pressure to spend on transition

    Canada's biggest oil sands producers are generating billions more in free cash flow in a faster-than-expected pandemic rebound, but taking a cautious approach to spending it that is disappointing environment-minded investors. Their strategy to repay debts and pay shareholders has won praise from investors in Canadian Natural Resources, Suncor Energy and Cenovus Energy who are eager for higher returns.

  • NZD/USD Forex Technical Analysis – New Minor Top Formed at .7034; Could Weaken on Close Under .6988 Pivot

    The direction of the NZD/USD into the close on Wednesday is likely to be determined by trader reaction to the minor pivot at .6989.

  • U.K.’s Giant Battery Factory Developer Looks for a SPAC Deal

    (Bloomberg) -- Britishvolt Ltd., the developer of the first giant battery factory in the U.K., is considering going public.The company has appointed Guggenheim Securities LLC and Barclays Plc as advisers to look into options including listing in the U.S. through a merger with a special purpose acquisition company, or SPAC, Orral Nadjari, founder and chief executive officer of Britishvolt, said in an interview. The deal could be announced as soon as the end of this quarter, he said.It’s the first time the company has talked in detail about its plans to finance the 2.6 billion-pound ($3.6 billion) project that will play a central role in delivering Prime Minister Boris Johnson’s green plan. The U.K. has banned sales of new gasoline and diesel cars by 2030, and needs a factory producing batteries for electric vehicles to avoid falling behind in the global race to lead manufacturing for the energy transition.“The SPAC market is very interesting and is the result of the very mature capital markets in the U.S. that have identified the industrial revolution that is happening now, when we go from the era of internal combustion engine towards an era of electrification,” Nadjari said. “There will be a lot of scale-ups that will need a lot of capital.”The company hasn’t identified any automotive customers yet, and it’s unclear if any automaker will agree on a supply deal with an upstart that’s still seeking funding. Nadjari, a former investment banker, says he’s not worried.By 2040, electric vehicles will make up two-thirds of total passenger car sales in Europe, with more 10 million units sold a year. That will make the continent the second-largest EV market, behind China and ahead of the U.S., according to BloombergNEF.If Britishvolt does agree to a SPAC deal, the target to announce it will be the end of the second quarter or beginning of the third, Nadjari said.Based in Blyth in northeast England, Britishvolt is planning to launch its series B funding round next week to raise as much as 100 million pounds, with Barclays as its financial adviser, Nadjari said. The round already has “a lot of interest” and series C will follow before summer with a cap of 250 million pounds.The series A funding round, which closed in February, made William Harrison, chief executive officer of private equity firm Cathexis Holdings LP, the second-largest shareholder, after Nadjari. Cathexis is the family office of Harrison investing from a low of $3 million in niche EV deals, to more than $100 million when buying established companies or financing infrastructure and real estate, according to its website.Because of its exit from the European Union, the U.K.’s auto industry has little time to localize production of batteries. The Brexit deal reached late in 2020 requires 30% of the content of battery packs for U.K.-built cars to be sourced domestically; the regulation gets tougher in 2024.“The new rules of origin should provide the conditions for the U.K. automotive industry to succeed,” said Stephen Gifford, chief economist at the Faraday Institution, which researches commercial battery developments. “But, to do so, it is now more important than ever that gigafactories are built in the U.K., and quickly, and with well-developed local supply chains.”Ministers are determined for the U.K. to stay in the mix of leading battery-makers in Europe. Johnson has committed 1 billion pounds to help build factories that can produce batteries at scale. Britishvolt has applied for some of the funding and is waiting to hear back.“We have had very fruitful conversations with the government,” Nadjari said. “Definitely government funding is critical for large industrial investment such as Britishvolt.”The Automotive Transformation Fund will likely support one, if not two, giant battery factories, according to the Advanced Propulsion Centre U.K., the non-profit acting as the delivery partner for the funding. The aim is to see the U.K. punch above its weight for battery making compared with the scale of its auto sector.The Faraday Institution estimates the U.K. will need seven giant factories by 2040, each producing 20 gigawatt-hours per year of batteries. Britishvolt is looking at building multiple plants in the U.K., Europe and elsewhere to produce 150 to 200 gigawatt-hours by 2030, Nadjari.“It’s a very exciting period and there is a lot of money in the capital markets looking at ESG propositions,” Nadjari said. “We are uniquely positioned to potentially become the British champion within the energy industry.”(Adds details about government funding in thirteenth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Exxon Mobil signals first profit in five quarters on price gains

    HOUSTON (Reuters) -Exxon Mobil Corp could post its first profit in five quarters on improved results across its businesses, with higher oil and gas prices providing a lift of as much as $2.7 billion, offset by costs from a February deep freeze. The largest U.S. oil producer last year posted consecutive quarterly losses as falling oil prices and refining margins triggered write downs. It slashed operating expenses last year and analysts had forecast a per share profit of 54 cents, according to IBES data from Refinitiv.

  • Market Wrap: Bitcoin Pushes $60K as Goldman, BlackRock Moves Signal Adoption

    Bitcoin finishes the first quarter double where it started the year, versus a 5.8% gain for the S&P 500. No wonder Goldman's clients want in.

  • USD/JPY Price Forecast – US Dollar Continues Parabolic Move

    The US dollar has rallied yet again during the trading session on Wednesday as this market seems to completely defy gravity.

  • E-mini S&P 500 Index (ES) Futures Technical Analysis – Could Strengthen Over 3971.25, Weaken Under 3928.75

    The direction of the June E-mini S&P 500 Index on Wednesday is likely to be determined by trader reaction to 3971.25 and 3928.75.

  • Greensill insurance mystery turns up the heat on Credit Suisse

    Credit Suisse told investors the debt in its $7.3 billion finance fund was low risk because it was insured but the bank failed to ensure the policies would pay out, two sources told Reuters. When Japan's Tokio Marine, the company insuring the debt, declined to renew its coverage with Greensill Capital last month, Credit Suisse was forced to liquidate the fund and said this may have a material impact on its results and reputation. The bank's shares have fallen by almost a quarter in the past month as it deals with the fallout from Greensill and the impact of losses at its prime brokerage division caused by the stricken U.S. fund Archegos.